English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA study of persons with gout and type 2 diabetes found that the use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) may reduce recurrent flares and gout-primary emergency department (ED) visits and hospitalizations compared to treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is). SGLT2is may also provide greater cardiovascular benefits in this population. The findings are published in Annals of Internal Medicine.
Tag: gout
New Look at an Ancient Disease: Study Finds Novel Treatment Targets for Gout
UC San Diego scientists identify a new molecular model and potential therapeutic target for gout, the most common form of inflammatory arthritis.
Study Finds Treat-to-Target ULT Strategy Manages Gout Effectively and Safely with No Cardiovascular Toxicity
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of patients reaching target urate levels. Additionally, both appeared safe, with no evidence of increased cardiovascular toxicity.
Gout Treatment Success Doubled by Combining Two Drugs, Study Finds
If left untreated, gout can cause severe disability. But unlike rheumatoid arthritis, there are only a handful of ways to treat it. Researchers say a combination of two existing drugs disrupts antibody production and doubles treatment efficacy.
“My Disease May Be Invisible, But I’m Not”: Patients Tell Their Stories During Rheumatic Disease Awareness Month
The American College of Rheumatology (ACR) and Simple Tasks™ will recognize the fifth annual Rheumatic Disease Awareness Month (RDAM) this September with an awareness campaign that focuses on amplifying patient voices and experiences.
ACR Releases Gout Management Guideline with Emphasis on Treat-to-Target Strategy for Urate Lowering Therapy
Today, the American College of Rheumatology (ACR) released the 2020 Guideline for the Management of Gout.
Blood pressure drug linked to lower risk of gout
A new study led by physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) reports that the antihypertensive drug amlodipine lowered long-term gout risk compared to two other drugs commonly prescribed to lower blood pressure. The findings are published in the Journal of Hypertension.
American College of Rheumatology Previews Draft of Updated Gout Treatment Guideline at the 2019 ACR/ARP Annual Meeting
The American College of Rheumatology (ACR) is previewing draft recommendations from an updated treatment guideline for managing patients with gout during the 2019 ACR/ARP Annual Meeting in Atlanta.
LARGE GENOME-WIDE ASSOCIATION STUDY ILLUMINATES GENETIC RISK FACTORS FOR GOUT
Researchers, using a method called genome-wide association study, have illuminated the genetic underpinnings of high serum urate, the blood condition that brings on gout.